ReviewCancers2021
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Pan-Cancer Targeted Sequencing Reveals Genomic Heterogeneity and Prognostic Subgroups in Urothelial Bladder Cancer.Cancers · 2026Article
- transFusion: a novel comprehensive platform for integration analysis of single-cell and spatial transcriptomics.Bioinformatics (Oxford, England) · 2026Article
- Impact of androgen receptor on triple negative breast cancer: a systematic review and meta-analytic study.BMJ public health · 2026Article
- SIRT3-IDH2 axis is a target of dietary fructose: implication of IDH2 as a key player in dietary carcinogen toxicity in mice colon.Experimental & molecular medicine · 2025Article
- Breast Cancer Bone Metastasis: Novel Prognostic Biomarkers Identified.Phenomics (Cham, Switzerland) · 2025Article
- Proteomic Analysis of Invasive Breast Cancer Cells Treated with CBD Reveals Proteins Associated with the Reversal of Their Epithelial-Mesenchymal Transition Induced by IL-1β.International journal of molecular sciences · 2025Article
- Unleashing the potential of Genistein and its derivatives as effective therapeutic agents for breast cancer treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Role of BRCA1 in glioblastoma etiology.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Higher inflammatory response in hepatocellular carcinoma is associated with immune cell infiltration and a better outcome.Hepatology international · 2024Article
- The effect of human umbilical cord mesenchymal stem cells conditioned medium combined with tamoxifen drug on BRCA1 and BRCA2 expression in breast cancer mouse models.Molecular biology reports · 2024Article
- BRCA1 mutation promotes sprouting angiogenesis in inflammatory cancer-associated fibroblast of triple-negative breast cancer.Cell death discovery · 2024Article
- Proteomic biomarkers profiling in Pakistani pancreatic ductal adenocarcinoma population: a retrospective cohort study.Biomarkers in medicine · 2024Article
- Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience.PloS one · 2024Article
- Detection of genomic variants in BRCA1 and BRCA2 across gastric cancer patients using next generation sequencing.American journal of translational research · 2024Article
- DNA methylation signatures provide novel diagnostic biomarkers and predict responses of immune therapy for breast cancer.Frontiers in genetics · 2024Article
- Thinking (Metastasis) outside the (Primary Tumor) Box.Cancers · 2023Article
- The mortalities of female-specific cancers in China and other countries with distinct socioeconomic statuses: A longitudinal study.Journal of advanced research · 2023Article
- Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers.Nucleic acids research · 2023Article
- Global trends inFrontiers in oncology · 2023Article
- Whole Exome Sequencing reveals clinically important pathogenic mutations in DNA repair genes across lung cancer patients.American journal of cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Heritable mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.